BEIJING: China has begun work on a facility to manufacture its first COVID-19 vaccine candidate that uses messenger RNA (mRNA) technology, even though the candidate is still in early-stage clinical trials, state-backed media reported on Monday (Dec 21).
The mRNA technology contains instructions for human cells to make proteins that mimic part of the coronavirus, and is used in vaccines from Moderna as well as from Pfizer and BioNTech. Both those vaccines have obtained efficacy data from late-stage, large-scale trials and emergency-use approval from the United States.
The plant for China’s mRNA candidate, which is being jointly developed by the Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences, could be operational within eight months, the official China News Service reported.
READ: China to start opening COVID-19 vaccination programme to general public
The facility will have a first-phase annual capacity of 120 million doses, the report said.
The candidate, known as ARCoV or ARCoVax, has entered a Phase 1b clinical trial in October after a Phase 1 trial that started in June, data on the website of Chinese Clinical Trial Registry show.
READ: China welcomes WHO-led trip to investigate COVID-19, WHO official says
READ: ‘We are not afraid’: Wuhan residents say they hope WHO team finds COVID-19 origins
At least five Chinese candidates have already entered Phase 3 clinical trials, three of which have been given to people of high infection risk via China’s emergency inoculation programme.
Those three are inactivated vaccines, which used inactivated or killed versions of the virus that cannot replicate in human cells to trigger immune responses.
BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments
Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram